In addition, COL6A1 expression level was closely associated with immunotherapy in patients with advanced bladder cancer, and bladder cancer patients with high COL6A1 expression showed poorer responsiveness and efficacy to immunotherapy. This evidence concerns the gene COL6A1 and urinary bladder cancer.